spacer
home > ict > autumn 2017 > time to listen
PUBLICATIONS
International Clinical Trials

Time to Listen

The new era of 2.0 technologies has welcomed the science
of pharmacovigilance (PV) with increasing interest from
regulatory agencies, pharmaceutical companies, healthcare
providers and patients, who may be seen as the leaders of
this evolution – as consumers of health-related products, the
collective voice of patients is having a significant impact. This
is contemporary to an observed shift from evidence-based
medicine towards real world evidence and observational
studies. In these, a study’s design is more fitted to patient life
than in controlled clinical trials, where eligible participants
must adapt to study settings.

Social media platforms, like Facebook, Twitter, and
Instagram, along with health-related websites and forums,
such as PatientsLikeMe or pharma-sponsored websites,
offer large forums of expression where any health-related
idea or concern may be shared, including adverse events
attributed to medications.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Senior Safety Scientist at UBC, Caroline Legendre is responsible for supporting operational PV functions, including client interface, deliverables related to product safety and safety signal detection and assessment. She has 10 years of experience in the global pharmaceutical industry, with expertise in vaccines, pre- and post-marketing PV and pharmacoepidemiology.

Alexis Pinçon is Safety Physician at UBC and responsible for providing medical support to operational PV functions. He completed his medical training at the University of Lyon, France, and received his Master of Public Health from Université Besançon (Franche-Comté) in 2007. He has 10 years’ experience in PV within the pharma industry, primarily focused on vaccines in both clinical development and post-marketing.
spacer
Caroline Legendre
spacer
spacer
spacer
Alexis Pinçon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Spirea Raises £2.4M ($3M) to Develop Antibody Drug Conjugates in Cancer

Cambridge, UK, 14 June 2022: Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of superior and differentiated ADCs in the treatment of solid tumours where there is a high unmet need.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement